Trials / Completed
CompletedNCT03588637
Real-world Daptomycin Use in Chinese ICUs
Real-world Effectiveness and Safety on Daptomycin in Gram-Positive Infections in Chinese Intensive Care Units
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (actual)
- Sponsor
- West China Hospital · Academic / Other
- Sex
- All
- Age
- 1 Year – 100 Years
- Healthy volunteers
- Not accepted
Summary
Analyze the effectiveness and safety of Daptomycin(Jiangsu Hengrui Medicine Co., Ltd) in Gram-positive infections in Chinese Intensive Care Units by using the real-world data platform, https://rws.scccmqc.com. Patients who received at least one dose of Daptomycin between 2016 to 2021 are eligible.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervention | No intervention |
Timeline
- Start date
- 2018-06-01
- Primary completion
- 2021-01-01
- Completion
- 2021-12-30
- First posted
- 2018-07-17
- Last updated
- 2022-07-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03588637. Inclusion in this directory is not an endorsement.